You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulpiride
Accession NumberDB00391  (APRD00032)
TypeSmall Molecule
GroupsApproved
DescriptionA dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
Structure
Thumb
Synonyms
(+-)-Sulpiride
5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
Levosulpirida
Levosulpiride
Levosulpiridum
N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide
Sulpirid
Sulpirida
Sulpiridum
Sulpyrid
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BosnylNot Available
DogmatilNot Available
DogmatylNot Available
DolmatilNot Available
EglonylNot Available
EspirideNot Available
MeresaNot Available
ModalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7MNE9M8287
CAS number15676-16-1
WeightAverage: 341.426
Monoisotopic: 341.140926929
Chemical FormulaC15H23N3O4S
InChI KeyInChIKey=BGRJTUBHPOOWDU-UHFFFAOYSA-N
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
IUPAC Name
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
SMILES
CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Salicylamide
  • Benzenesulfonamide
  • Benzoic acid or derivatives
  • Benzamide
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationSulpiride is indicated for the treatment of schizophrenia.
PharmacodynamicsSulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.
Mechanism of actionIn contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.
Related Articles
AbsorptionSulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life6 to 8 hours
ClearanceNot Available
ToxicitySulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9444
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7319
P-glycoprotein inhibitor INon-inhibitor0.857
P-glycoprotein inhibitor IINon-inhibitor0.8994
Renal organic cation transporterNon-inhibitor0.7685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.54
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9656
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9409
Ames testNon AMES toxic0.6229
CarcinogenicityNon-carcinogens0.7139
BiodegradationNot ready biodegradable0.8542
Rat acute toxicity1.8612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8546
hERG inhibition (predictor II)Inhibitor0.549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178 dec °CPhysProp
water solubility2280 mg/LNot Available
logP0.57HOEGBERG,T ET AL. 1986
Caco2 permeability-6.16ADME Research, USCD
pKa9.12EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.537 mg/mLALOGPS
logP1.2ALOGPS
logP0.22ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.24ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity88.63 m3·mol-1ChemAxon
Polarizability36.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AL07N05AL01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sulpiride.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sulpiride.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Sulpiride.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigitoxin.
AclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Aclidinium.
adipiplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alprazolam.
Aluminum hydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum phosphate.
Aminohippuric acidThe risk or severity of adverse effects can be increased when Aminohippuric acid is combined with Sulpiride.
AmisulprideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sulpiride.
AmobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Sulpiride.
AmphetamineSulpiride may decrease the stimulatory activities of Amphetamine.
Anisotropine MethylbromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Anisotropine Methylbromide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.
ArticaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Sulpiride.
Atracurium besylateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atracurium besylate.
AtropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atropine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Sulpiride.
AzelastineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Sulpiride.
BaclofenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.
BenactyzineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benactyzine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sulpiride.
BenzatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benzatropine.
BenzocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzocaine.
BenzphetamineSulpiride may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzyl alcohol.
BezafibrateThe risk or severity of adverse effects can be increased when Bezafibrate is combined with Sulpiride.
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Sulpiride.
BiperidenThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Biperiden.
Bismuth SubcitrateThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth Subcitrate.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sulpiride.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
BrimonidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.
BrompheniramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.
BuprenorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sulpiride.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.
ButacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butorphanol.
CabergolineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cabergoline.
Calcium carbonateThe serum concentration of Sulpiride can be decreased when it is combined with Calcium carbonate.
CarbamazepineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Sulpiride.
CarisoprodolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.
ChlorphenamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorphenamine.
ChlorphenoxamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Chlorphenoxamine.
ChlorphentermineSulpiride may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sulpiride.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cinchocaine.
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Sulpiride.
CitalopramThe risk or severity of adverse effects can be increased when Sulpiride is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sulpiride.
CocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sulpiride.
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Sulpiride.
CyclizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.
CyclopentolateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclopentolate.
CyproheptadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sulpiride.
DapoxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dapoxetine.
DarifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.
deramciclaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Sulpiride.
DeslanosideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.
DesloratadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.
DetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexbrompheniramine.
DexetimideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dexetimide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexmedetomidine.
DextroamphetamineSulpiride may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sulpiride.
DextromoramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diazepam.
DicyclomineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.
DifenoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Difenoxin.
DigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.
DihydroetorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Sulpiride.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
DoxylamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Sulpiride is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Sulpiride.
DrotebanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.
DyclonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Sulpiride is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Sulpiride is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sulpiride.
EntacaponeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sulpiride.
EscitalopramThe risk or severity of adverse effects can be increased when Sulpiride is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eszopiclone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.
EthanolSulpiride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Sulpiride.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.
EthopropazineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ethopropazine.
EthosuximideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.
EtoperidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sulpiride.
FenfluramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sulpiride.
FesoterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.
FexofenadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.
FlurazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sulpiride.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sulpiride.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.
GabapentinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Sulpiride is combined with gabapentin enacarbil.
Gallamine TriethiodideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Gallamine Triethiodide.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Glutethimide.
GlycopyrroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Glycopyrronium.
GuanfacineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.
HalothaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Heroin.
HexamethoniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hexamethonium.
HexobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hexobarbital.
HomatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Homatropine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sulpiride.
HydrocodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sulpiride.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.
Hydroxyamphetamine hydrobromideSulpiride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
HydroxyzineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hydroxyzine.
HyoscyamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hyoscyamine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sulpiride.
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Sulpiride.
IndalpineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.
Ipratropium bromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sulpiride.
IsofluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocetirizine.
LevodopaThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sulpiride.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulpiride.
LisdexamfetamineSulpiride may decrease the stimulatory activities of Lisdexamfetamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Sulpiride.
LofentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sulpiride.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sulpiride.
Lu AA21004The risk or severity of adverse effects can be increased when Sulpiride is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.
MagaldrateThe serum concentration of Sulpiride can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium oxide.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Magnesium Sulfate.
Magnesium TrisilicateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Trisilicate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sulpiride.
MecamylamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Sulpiride is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Sulpiride.
MephentermineSulpiride may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.
MequitazineSulpiride may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sulpiride.
MetaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methadyl Acetate.
MethamphetamineSulpiride may decrease the stimulatory activities of Methamphetamine.
MethanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methantheline.
MethapyrileneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sulpiride.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.
MethylphenidateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital.
MetixeneThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Metixene.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.
MetyrosineSulpiride may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Sulpiride.
MidazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Sulpiride is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
MirtazapineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sulpiride.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sulpiride.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Sulpiride.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.
N-butylscopolammonium bromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with N-butylscopolammonium bromide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
NabiloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.
NitrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sulpiride.
NVA237The therapeutic efficacy of Sulpiride can be decreased when used in combination with NVA237.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.
OlopatadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sulpiride.
OpiumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Opium.
OrphenadrineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Orphenadrine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Sulpiride.
OuabainThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ouabain.
OxazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxybuprocaine.
OxybutyninThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxymorphone.
OxyphenoniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxyphenonium.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.
PancuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pancuronium.
ParaldehydeSulpiride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Sulpiride.
ParoxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sulpiride.
PentoliniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pentolinium.
PerampanelThe risk or severity of adverse effects can be increased when Sulpiride is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Sulpiride.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sulpiride.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sulpiride.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sulpiride.
PhenobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenoxyethanol.
PhentermineSulpiride may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sulpiride.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sulpiride.
PipecuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pipecuronium.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sulpiride.
PirenzepineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pirenzepine.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.
PizotifenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Sulpiride.
PomalidomideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.
PramipexoleSulpiride may increase the sedative activities of Pramipexole.
PramipexoleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sulpiride.
PrilocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Primidone.
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.
ProcaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.
ProcyclidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Procyclidine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Sulpiride.
PropanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propantheline.
ProparacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Sulpiride.
PropofolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sulpiride.
PSD502The risk or severity of adverse effects can be increased when Sulpiride is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Sulpiride.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride.
QuinidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinidine.
RamelteonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.
RemifentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sulpiride.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sulpiride.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sulpiride.
RomifidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Romifidine.
RopiniroleSulpiride may increase the sedative activities of Ropinirole.
RopiniroleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride.
RotigotineSulpiride may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sulpiride.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Sulpiride is combined with S-Ethylisothiourea.
ScopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Scopolamine.
Scopolamine butylbromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine butylbromide.
SecobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Sulpiride.
SertralineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sodium oxybate.
SolifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Solifenacin.
StiripentolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Stiripentol.
SucralfateThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.
SufentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Sulpiride is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Sulpiride.
TasimelteonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sulpiride.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sulpiride.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.
TetracaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetrodotoxin.
ThalidomideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sulpiride.
ThiamylalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Sulpiride.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.
TiagabineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiletamine.
TiotropiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tiotropium.
TizanidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tolcapone.
TolterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sulpiride.
TrazodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sulpiride.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulpiride.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sulpiride.
TrihexyphenidylThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trihexyphenidyl.
TrimethaphanThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimethaphan.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sulpiride.
TriprolidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triprolidine.
TropicamideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tropicamide.
TrospiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trospium.
TubocurarineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tubocurarine.
UmeclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Umeclidinium.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sulpiride.
VecuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Vecuronium.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Sulpiride.
VigabatrinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.
ZoaleneThe risk or severity of adverse effects can be increased when Zoalene is combined with Sulpiride.
ZolazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sulpiride.
ZolpidemThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Sulpiride.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Jaber M, Tison F, Fournier MC, Bloch B: Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res. 1994 Apr;23(1-2):14-20. [PubMed:7518029 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7. [PubMed:19795811 ]
  2. Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40. doi: 10.1111/j.1460-9568.2008.06423.x. [PubMed:18973551 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [PubMed:3823608 ]
  2. Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [PubMed:577162 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23